金因康®Diquafosol Sodium Eye Drops
Following the launch of GeneSoft®,金因康® became the second ophthalmic drug to receive market approval from the China NMPA in May 2025, offering a novel therapeutic option for dry eye disease.
金因康® is indicated for patients diagnosed with dry eye accompanied by keratoconjunctival epithelial damage associated with tear deficiency.
3% (0.4ml : 12mg)
Mechanism of Action
Diquafosol sodium activates P2Y2 receptors, stimulating ocular surface epithelial cells to secrete fluid, mucin, and lipids. This action restores and stabilizes the tear film, while exerting anti-inflammatory effects and promoting corneal healing, thereby significantly improving dry eye symptoms.
Product Advantages
-
Addresses tear film instability at its source and repairs corneal epithelial damage -
Provides targeted therapy for dry eye patients with tear deficiency-associated corneal epithelial defects -
Represents a new-generation, more effective and patient-friendly therapeutic option
More Products
-
Pinup®Voriconazole TabletsPinup® represent a broad-spectrum triazole antifungal agent indicated for the treatment of the following fungal infections in adult and pediatric patients aged 2 years and older
-
Boshutai®Acarbose TabletsAs an adjunct to dietary control for: (1) Type 2 diabetes (2) Reducing postprandial blood glucose in individuals with impaired glucose tolerance
-
金因康®Diquafosol Sodium Eye Drops金因康® is indicated for patients diagnosed with dry eye accompanied by keratoconjunctival epithelial damage associated with tear deficiency.
